AI Science Tracker
EN

Random forests capture cancer-specific variation in measured immune-cell response assays

University of Science and Technology of China · 31 Oct 2025 · biology

Discovery

Random forests capture cancer-specific variation in measured immune-cell response assays

Source check: Source checked. Not independent scientific confirmation.

Finding: Random-forest models combined receptor–ligand expression measurements to estimate experimentally observed natural-killer-cell responses to tumor samples. Cancer-specific models generalized better within their studied cancer types than a pan-cancer model, whose separate-test AUC fell to 0.638. This is assay-level biological model validation, without established clinical treatment-selection benefit.

Technology: Random forests combining receptor–ligand expression features for assay-response classification

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Random forests learned nonlinear combinations of expression features linked to measured assay outcomes, enabling the observed distinction between cancer-specific and pan-cancer response prediction. Generic classifier benchmarks alone and untested clinical benefit are not the admitted claim.
Test and result
The source analyzed 76 distinct NK-cell samples against fourteen ovarian-cancer cell lines, then extended modeling across cancers. Random forests used 70:30 training/test partitions, ten-fold grid-search tuning and twenty random repetitions. A separate pan-cancer test set produced AUC 0.638 and accuracy 63.52%; source-reported breast- and gastric-cancer models reached separate-test AUCs 0.831 and 0.865. The result concerns measured assay response and its cancer-dependent generalization.
Limitation / still unknown
Random tumor–immune-cell pair partitions do not establish complete donor/cell-line independence; shared entities could affect apparent generalization. Upstream feature screening isolation and supplementary pair-level reconstruction were not verified. Five patient-derived AML samples and one treated patient do not establish prospective clinical efficacy or broad therapy-selection utility. Operational cell preparation, experimental manipulation and treatment protocols were not adjudicated.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://link.springer.com/article/10.1007/s13402-025-01113-1

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 21 Nov 2026. Review scope: Read actual primary computational model construction/tuning Methods and ovarian/pan-cancer/cancer-specific assay-prediction Results, plus high-level AML validation limitations. Operational biological preparation/manipulation protocols and supplements were not processed or adjudicated. Existing-data assay evaluation is classified retrospectively. Exact original article front DOI/title and fresh PubMed primary relationship metadata checked..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 1/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse biology discoveries.